| News

Aging: The Tsunami for Healthcare


Humanity is growing older. According to the UN the number of people in the world aged 60 years or over is projected to double to 2.1 billion by 2050. In developed countries, more than one third of the population will be over 60 by this time. The number of people over 80 will increase even faster to 434 million from 125 million in 2017. Meanwhile the working age population, who are needed to pay or provide support for the elderly, will only increase by about 25 percent over the same time.

From the left side: Thomas Brenzikofer (DayOne/ BaselArea.swiss), Szofia Bullain (MD Geriatric Neurologist), Antonella Santuccione (Woman’s Brain Project and Roche Diagnostics), Hansruedi Voelkle (EUPATI), Manfred Eggersdorfer, (DSM Nutritional Products), Andy Bushell (Novartis), Mieke Deschodt (University of Basel)

These numbers make clear: The question mark in the title of the DayOne Experts Event “Aging – the game changer for healthcare?” is actually redundant. The game simply has to be changed! The speakers and panelists at the event that took place in Basel on February 26 agreed that healthcare as we know it will not be able to cope with the tsunami of aging. Under this perspective, aging not only represents a threat, but also an opportunity, for it will compel the industry to make the systematic changes that are required for the overall improvement of healthcare. Therefore aging can and should also be perceived as an interesting market for healthcare innovation.

But where to begin? This is what we learned from the speakers and panelists at the DayOne Expert Event:

1) Healthcare as we know it has been built for acute care: from infrastructure to career plans, research incentives and reimbursement schemes, healthcare professionals are trained to fix and rescue lives. But when it comes to long-term care and treatment this acute system is highly inefficient and costly. A possible way forward was presented by Mieke Deschodt from the University of Basel, who presented the novel care concept INSPIRE, which will be implemented in the canton of Baselland.

2) A big research effort is needed to better diagnose, treat and most of all prevent the disease burdens of an aging population. As Antonella Santuccione from the Woman’s Brain Project stated: It takes weeks to diagnose a tumor, but years to diagnose Alzheimer’s. And the significant differences in disease progression in terms of gender shows that a precision medicine approach is very much needed to make progress in treating disorders that are typical to aging.

3) The best way to cope with the tsunami of aging is actually by staying healthy – not only as long as possible but preferably to the end of life. In this perspective, we have to shift our mindset from neglecting or avoiding aging to aging successfully. And as the findings of the 90+ Study show, presented by geriatric neurologist Szofia Bullain, this will need a more holistic view on health, as psychological and social implications seem to count much more than physical activities and healthy nutrition alone for successful aging.

4) The right use and bold implementation of technology, most of all digital technology, will be crucial. But a lifelong approach will also be needed. Knowing the genetic preposition would allow for better monitoring and nudging an individual to healthy behavior, thereby preventing the occurrence of disease in old age starting from the very beginning of our lifespan. But to actually make this happen a first important step will be to set up a trusted platform which allows citizens to share their health data with all stakeholders.

A big thank you to all the speakers and panelists for sharing their great stories and very valuable insights:

Mieke Deschodt, University of Basel
Antonella Santuccione, Woman’s Brain Project and Roche Diagnostic
Szofia Bullain, MD Geriatric Neurologist
Manfred Eggersdorfer, DSM Nutritional Products
Andy Bushell, Novartis
Hansruedi Voelkle, EUPATI


Slides presented at the Event

Presentation by Antonella Santuccione from Woman’s Brain Project and Roche Diagnostic

Presentation by Mieke Deschodt from the University of Basel

Presentatio by Szofia Bullain from MD Geriatric Neurologist

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest

Moderna driving forward production of vaccine from Basel

Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel is “probably the most productive life sciences location in the world”

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area cantons publish joint economic report

The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.

Read More
Basel Area Business & Innovation, Innovation

Resistell receives high-level EU grant

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.